Bypassing the EPR effect with a nanomedicine harboring a sustained-release function allows better tumor control

Bypassing the EPR effect with a nanomedicine harboring a sustained-release function allows better tumor control

The current enhanced permeability and retention (EPR)-based approved nanomedicines have had little impact in terms of prolongation of overall survival in patients with cancer. For example, the two Phase III trials comparing Doxil®, the first nanomedicine approved by the US Food and Drug Administrati...

Full description

Bibliographic Details
Main Authors: Shen, Yao An, Shyu, Ing Luen, Lu, Maggie, He, Chun Lin, Hsu, Yen Mei, Liang, Hsiang Fa, Liu, Chih Peng, Liu, Ren Shyan, Shen, Biing Jiun, Wei, Yau Huei, Chuang, Chi Mu
Other Authors: School of Humanities and Social Sciences
Format: Journal Article
Language:English
Published: 2015
Subjects:
DRNTU::Science::Medicine
Online Access:https://hdl.handle.net/10356/107443
http://hdl.handle.net/10220/25625

Similar Items

Similar Items